IBRX
Price
$5.15
Change
-$0.30 (-5.50%)
Updated
Nov 12, 03:25 PM (EDT)
3 days until earnings call
SAVA
Price
$26.46
Change
-$0.60 (-2.22%)
Updated
Nov 12, 03:36 PM (EDT)
112 days until earnings call
Ad is loading...

IBRX vs SAVA

Header iconIBRX vs SAVA Comparison
Open Charts IBRX vs SAVABanner chart's image
ImmunityBio
Price$5.15
Change-$0.30 (-5.50%)
Volume$3.79K
CapitalizationN/A
Cassava Sciences
Price$26.46
Change-$0.60 (-2.22%)
Volume$150
CapitalizationN/A
IBRX vs SAVA Comparison Chart
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
IBRX vs. SAVA commentary
Nov 12, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Hold and SAVA is a Buy.

COMPARISON
Comparison
Nov 12, 2024
Stock price -- (IBRX: $5.44 vs. SAVA: $27.03)
Brand notoriety: IBRX and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 91% vs. SAVA: 68%
Market capitalization -- IBRX: $3.79B vs. SAVA: $1.3B
IBRX [@Biotechnology] is valued at $3.79B. SAVA’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $476.71B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 0 FA rating(s) are green whileSAVA’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 0 green, 5 red.
  • SAVA’s FA Score: 0 green, 5 red.
According to our system of comparison, SAVA is a better buy in the long-term than IBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 5 TA indicator(s) are bullish while SAVA’s TA Score has 6 bullish TA indicator(s).

  • IBRX’s TA Score: 5 bullish, 4 bearish.
  • SAVA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а +4.62% price change this week, while SAVA (@Biotechnology) price change was +4.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +11.71%, and the average quarterly price growth was +7.66%.

Reported Earning Dates

IBRX is expected to report earnings on Mar 04, 2025.

SAVA is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($3.79B) has a higher market cap than SAVA($1.3B). SAVA YTD gains are higher at: 20.080 vs. IBRX (8.367). SAVA has higher annual earnings (EBITDA): -130.64M vs. IBRX (-436.05M). IBRX has more cash in the bank: 218M vs. SAVA (207M). SAVA has less debt than IBRX: SAVA (0) vs IBRX (736M). IBRX has higher revenues than SAVA: IBRX (1.31M) vs SAVA (0).
IBRXSAVAIBRX / SAVA
Capitalization3.79B1.3B291%
EBITDA-436.05M-130.64M334%
Gain YTD8.36720.08042%
P/E RatioN/AN/A-
Revenue1.31M0-
Total Cash218M207M105%
Total Debt736M0-
FUNDAMENTALS RATINGS
IBRX vs SAVA: Fundamental Ratings
IBRX
SAVA
OUTLOOK RATING
1..100
2163
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
8676
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
3742
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3142

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (63) in the Pharmaceuticals Other industry is in the same range as IBRX (86) in the Biotechnology industry. This means that SAVA’s stock grew similarly to IBRX’s over the last 12 months.

SAVA's Profit vs Risk Rating (76) in the Pharmaceuticals Other industry is in the same range as IBRX (86) in the Biotechnology industry. This means that SAVA’s stock grew similarly to IBRX’s over the last 12 months.

SAVA's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as IBRX (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to IBRX’s over the last 12 months.

IBRX's Price Growth Rating (37) in the Biotechnology industry is in the same range as SAVA (42) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to SAVA’s over the last 12 months.

IBRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SAVA (100) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXSAVA
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
87%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IAXTX9.130.09
+1.00%
VY® T. Rowe Price Divers Mid Cap Gr S2
MLORX8.980.06
+0.67%
Cohen & Steers Future of Energy R
TMSIX39.590.25
+0.64%
Thrivent Mid Cap Stock S
DMCYX35.120.18
+0.52%
BNY Mellon Opportunistic Midcap Value Y
RLEFX36.87-0.05
-0.14%
American Funds American Balanced R5E

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-2.33%
AXON - IBRX
48%
Loosely correlated
+2.15%
ARRY - IBRX
41%
Loosely correlated
+10.43%
RXRX - IBRX
39%
Loosely correlated
+10.42%
AMRN - IBRX
37%
Loosely correlated
-2.57%
VCYT - IBRX
35%
Loosely correlated
+6.58%
More

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
+0.30%
CRSP - SAVA
35%
Loosely correlated
+6.28%
IBRX - SAVA
29%
Poorly correlated
-2.33%
ATXI - SAVA
27%
Poorly correlated
-8.68%
LXRX - SAVA
26%
Poorly correlated
N/A
AMRN - SAVA
26%
Poorly correlated
-2.57%
More